HC Wainwright reissued their buy rating on shares of Generate Biomedicines (NASDAQ:GENB – Free Report) in a research note published on Tuesday,Benzinga reports. The firm currently has a $30.00 price objective on the stock. A number of other research analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Generate […]

HC Wainwright reiterated their buy rating on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $52.00 target price on the stock. NAMS has been the topic of several other reports. Royal Bank Of Canada lowered their target price on shares […]

HC Wainwright reiterated their buy rating on shares of enGene (NASDAQ:ENGN – Free Report) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock. Several other research firms have also recently issued reports on ENGN. Morgan Stanley cut enGene from an “equal weight” rating to an “underweight” […]

Immunic (NASDAQ:IMUX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $22.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 80.48% from the stock’s previous close. IMUX […]

Scholar Rock (NASDAQ:SRRK – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $65.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 17.48% from the company’s current price. […]

Western Copper and Gold (NYSEAMERICAN:WRN – Get Free Report) (TSE:WRN)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Friday, MarketBeat Ratings reports. They currently have a $5.75 price target on the stock. HC Wainwright’s price target points to a potential upside of 138.59% from the company’s […]

PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 303.23% from the company’s current […]

First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $57.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 25.88% from the stock’s current price. […]

HC Wainwright restated their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report sent to investors on Monday,Benzinga reports. They currently have a $140.00 price objective on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on the company. Mizuho lifted their price target on Cytokinetics from […]

Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 84.33% from the stock’s previous close. A number […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $455.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 84.88% from the company’s current price. […]

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $115.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 88.37% from the stock’s previous close. IONS has […]